ESCaPE-CMD (CLBS16)

Study Information

ESCaPE-CMD is a Phase 2 study evaluating an autologous CD34 cell therapy (CLBS16) for the treatment of coronary microvascular dysfunction (CMD) at two centers in the United States. For more information on this study, please visit www.escapecmd.com.
Status: Active - Fully Enrolled